Tirzepatide is a GLP-1 and GIP receptor agonist licensed in the UK for type 2 diabetes mellitus treatment Lightheadedness occurs through reduced fluid intake from gastrointestinal effects, blood pressure lowering from weight loss, or hypoglycaemia when combined with insulin or sulfonylureas Seek immediate medical attention for loss of consciousness, chest pain, severe confusion, or persistent vomiting preventing fluid intake Management includes maintaining adequate hydration (6-8 glasses daily), eating regular small meals, rising gradually from sitting or lying positions, and medication review with your GP Report frequent or concerning lightheadedness to your healthcare team within 24 hours for dose adjustment or investigation of alternative causes Table of Contents Why Mounjaro Can Cause Lightheadedness Mounjaro (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus
MT-1 shows high selectivity for MC1R receptors with minimal MC3R/MC4R cross-reactivity, meaning it produces melanogenesis without the appetite suppression or sexual side effects characteristic of melanotan-2
However, excessive exercise and overtraining can have adverse effects, so it's important to follow a balanced exercise program
Once you reach your target dose around week 46, you'll likely enter a maintenance phase lasting weeks and months
